nodes	percent_of_prediction	percent_of_DWPC	metapath
Carfilzomib—Pentagastrin—Goserelin—prostate cancer	0.483	1	CrCrCtD
Carfilzomib—ABCB1—Estramustine—prostate cancer	0.032	0.2	CbGbCtD
Carfilzomib—ABCB1—Cabazitaxel—prostate cancer	0.0211	0.132	CbGbCtD
Carfilzomib—ABCB1—Estrone—prostate cancer	0.0206	0.129	CbGbCtD
Carfilzomib—ABCB1—Ethinyl Estradiol—prostate cancer	0.0184	0.115	CbGbCtD
Carfilzomib—ABCB1—Conjugated Estrogens—prostate cancer	0.0135	0.0843	CbGbCtD
Carfilzomib—ABCB1—Mitoxantrone—prostate cancer	0.0123	0.0767	CbGbCtD
Carfilzomib—ABCB1—Estradiol—prostate cancer	0.0119	0.074	CbGbCtD
Carfilzomib—ABCB1—Prednisone—prostate cancer	0.0102	0.0637	CbGbCtD
Carfilzomib—ABCB1—Etoposide—prostate cancer	0.00774	0.0483	CbGbCtD
Carfilzomib—ABCB1—Docetaxel—prostate cancer	0.00708	0.0442	CbGbCtD
Carfilzomib—PSMB10—prostate gland—prostate cancer	0.00573	0.0897	CbGeAlD
Carfilzomib—ABCB1—Doxorubicin—prostate cancer	0.00528	0.033	CbGbCtD
Carfilzomib—PSMB8—prostate gland—prostate cancer	0.00369	0.0578	CbGeAlD
Carfilzomib—PSMB5—prostate gland—prostate cancer	0.00326	0.0511	CbGeAlD
Carfilzomib—PSMB8—seminal vesicle—prostate cancer	0.00312	0.0489	CbGeAlD
Carfilzomib—PSMB1—prostate gland—prostate cancer	0.00285	0.0447	CbGeAlD
Carfilzomib—PSMB2—prostate gland—prostate cancer	0.00278	0.0436	CbGeAlD
Carfilzomib—PSMB5—seminal vesicle—prostate cancer	0.00276	0.0432	CbGeAlD
Carfilzomib—PSMB10—testis—prostate cancer	0.00252	0.0395	CbGeAlD
Carfilzomib—PSMB8—urethra—prostate cancer	0.00247	0.0387	CbGeAlD
Carfilzomib—PSMB1—seminal vesicle—prostate cancer	0.00241	0.0378	CbGeAlD
Carfilzomib—PSMB2—seminal vesicle—prostate cancer	0.00235	0.0368	CbGeAlD
Carfilzomib—PSMB5—urethra—prostate cancer	0.00218	0.0342	CbGeAlD
Carfilzomib—PSMB1—renal system—prostate cancer	0.00194	0.0304	CbGeAlD
Carfilzomib—PSMB1—urethra—prostate cancer	0.00191	0.0299	CbGeAlD
Carfilzomib—PSMB8—bone marrow—prostate cancer	0.0019	0.0298	CbGeAlD
Carfilzomib—PSMB2—renal system—prostate cancer	0.00189	0.0297	CbGeAlD
Carfilzomib—PSMB2—urethra—prostate cancer	0.00186	0.0292	CbGeAlD
Carfilzomib—PSMB10—lymph node—prostate cancer	0.00183	0.0287	CbGeAlD
Carfilzomib—PSMB5—bone marrow—prostate cancer	0.00168	0.0263	CbGeAlD
Carfilzomib—PSMB8—testis—prostate cancer	0.00163	0.0255	CbGeAlD
Carfilzomib—PSMB1—bone marrow—prostate cancer	0.00147	0.023	CbGeAlD
Carfilzomib—PSMB5—testis—prostate cancer	0.00144	0.0225	CbGeAlD
Carfilzomib—PSMB2—bone marrow—prostate cancer	0.00143	0.0225	CbGeAlD
Carfilzomib—PSMB1—testis—prostate cancer	0.00125	0.0197	CbGeAlD
Carfilzomib—PSMB2—testis—prostate cancer	0.00122	0.0192	CbGeAlD
Carfilzomib—PSMB8—lymph node—prostate cancer	0.00118	0.0185	CbGeAlD
Carfilzomib—PSMB5—lymph node—prostate cancer	0.00104	0.0163	CbGeAlD
Carfilzomib—PSMB1—lymph node—prostate cancer	0.00091	0.0143	CbGeAlD
Carfilzomib—PSMB2—lymph node—prostate cancer	0.000887	0.0139	CbGeAlD
Carfilzomib—PSMB8—Estradiol valerate/Dienogest—Estrone—prostate cancer	0.000586	0.172	CbGdCrCtD
Carfilzomib—Ritonavir—CYP3A5—prostate cancer	0.000576	0.242	CrCbGaD
Carfilzomib—PSMB8—Testosterone Propionate—Estradiol valerate/Dienogest—prostate cancer	0.000498	0.146	CbGdCrCtD
Carfilzomib—Lopinavir—CYP2C19—prostate cancer	0.000466	0.196	CrCbGaD
Carfilzomib—PSMB8—Estradiol valerate/Dienogest—Estradiol—prostate cancer	0.000444	0.13	CbGdCrCtD
Carfilzomib—PSMB8—Estradiol valerate/Dienogest—Ethinyl Estradiol—prostate cancer	0.000433	0.127	CbGdCrCtD
Carfilzomib—ABCB1—prostate gland—prostate cancer	0.000425	0.00666	CbGeAlD
Carfilzomib—PSMB8—Podofilox—Etoposide—prostate cancer	0.000417	0.122	CbGdCrCtD
Carfilzomib—Ritonavir—CYP2E1—prostate cancer	0.000396	0.167	CrCbGaD
Carfilzomib—Ritonavir—CYP2C19—prostate cancer	0.000392	0.165	CrCbGaD
Carfilzomib—ABCB1—seminal vesicle—prostate cancer	0.000359	0.00563	CbGeAlD
Carfilzomib—ABCB1—epithelium—prostate cancer	0.000312	0.00489	CbGeAlD
Carfilzomib—Lopinavir—CYP3A4—prostate cancer	0.000297	0.125	CrCbGaD
Carfilzomib—ABCB1—renal system—prostate cancer	0.000289	0.00454	CbGeAlD
Carfilzomib—ABCB1—urethra—prostate cancer	0.000284	0.00446	CbGeAlD
Carfilzomib—Ritonavir—CYP3A4—prostate cancer	0.000249	0.105	CrCbGaD
Carfilzomib—ABCB1—bone marrow—prostate cancer	0.000219	0.00343	CbGeAlD
Carfilzomib—PSMB9—Betamethasone—Prednisone—prostate cancer	0.000201	0.0589	CbGdCrCtD
Carfilzomib—PSMB9—Dexamethasone—Prednisone—prostate cancer	0.000201	0.0589	CbGdCrCtD
Carfilzomib—ABCB1—testis—prostate cancer	0.000187	0.00293	CbGeAlD
Carfilzomib—PSMB8—Norethindrone—Ethinyl Estradiol—prostate cancer	0.000186	0.0547	CbGdCrCtD
Carfilzomib—PSMB8—Levonorgestrel—Ethinyl Estradiol—prostate cancer	0.000148	0.0435	CbGdCrCtD
Carfilzomib—ABCB1—lymph node—prostate cancer	0.000136	0.00213	CbGeAlD
Carfilzomib—Neutropenia—Capecitabine—prostate cancer	0.000125	0.000883	CcSEcCtD
Carfilzomib—Leukopenia—Mitoxantrone—prostate cancer	0.000124	0.00088	CcSEcCtD
Carfilzomib—Upper respiratory tract infection—Capecitabine—prostate cancer	0.000124	0.000877	CcSEcCtD
Carfilzomib—Pneumonia—Docetaxel—prostate cancer	0.000124	0.000874	CcSEcCtD
Carfilzomib—Dizziness—Ethinyl Estradiol—prostate cancer	0.000123	0.000872	CcSEcCtD
Carfilzomib—Cardiac disorder—Etoposide—prostate cancer	0.000123	0.000871	CcSEcCtD
Carfilzomib—Body temperature increased—Goserelin—prostate cancer	0.000121	0.000858	CcSEcCtD
Carfilzomib—Cough—Mitoxantrone—prostate cancer	0.000121	0.000858	CcSEcCtD
Carfilzomib—Acute coronary syndrome—Docetaxel—prostate cancer	0.000121	0.000857	CcSEcCtD
Carfilzomib—Infection—Estradiol—prostate cancer	0.000121	0.000855	CcSEcCtD
Carfilzomib—Renal failure—Docetaxel—prostate cancer	0.000121	0.000854	CcSEcCtD
Carfilzomib—Neuropathy peripheral—Docetaxel—prostate cancer	0.000121	0.000852	CcSEcCtD
Carfilzomib—Hyperglycaemia—Capecitabine—prostate cancer	0.00012	0.000851	CcSEcCtD
Carfilzomib—Body temperature increased—Conjugated Estrogens—prostate cancer	0.00012	0.00085	CcSEcCtD
Carfilzomib—Hypertension—Mitoxantrone—prostate cancer	0.00012	0.000848	CcSEcCtD
Carfilzomib—Hepatic failure—Epirubicin—prostate cancer	0.00012	0.000847	CcSEcCtD
Carfilzomib—Pneumonia—Capecitabine—prostate cancer	0.00012	0.000846	CcSEcCtD
Carfilzomib—Chills—Etoposide—prostate cancer	0.000119	0.000843	CcSEcCtD
Carfilzomib—Sepsis—Doxorubicin—prostate cancer	0.000119	0.000842	CcSEcCtD
Carfilzomib—Cardiac failure congestive—Epirubicin—prostate cancer	0.000119	0.000839	CcSEcCtD
Carfilzomib—Vomiting—Ethinyl Estradiol—prostate cancer	0.000119	0.000839	CcSEcCtD
Carfilzomib—Arthralgia—Mitoxantrone—prostate cancer	0.000118	0.000837	CcSEcCtD
Carfilzomib—Acute coronary syndrome—Capecitabine—prostate cancer	0.000117	0.00083	CcSEcCtD
Carfilzomib—Renal failure—Capecitabine—prostate cancer	0.000117	0.000827	CcSEcCtD
Carfilzomib—Headache—Ethinyl Estradiol—prostate cancer	0.000117	0.000826	CcSEcCtD
Carfilzomib—Neuropathy peripheral—Capecitabine—prostate cancer	0.000117	0.000825	CcSEcCtD
Carfilzomib—Renal failure acute—Epirubicin—prostate cancer	0.000117	0.000824	CcSEcCtD
Carfilzomib—PSMB8—Fluorometholone—Prednisone—prostate cancer	0.000113	0.0333	CbGdCrCtD
Carfilzomib—Infection—Mitoxantrone—prostate cancer	0.000113	0.000797	CcSEcCtD
Carfilzomib—Back pain—Etoposide—prostate cancer	0.000112	0.000791	CcSEcCtD
Carfilzomib—Neutropenia—Prednisone—prostate cancer	0.000111	0.000786	CcSEcCtD
Carfilzomib—Muscle spasms—Etoposide—prostate cancer	0.000111	0.000786	CcSEcCtD
Carfilzomib—Thrombocytopenia—Mitoxantrone—prostate cancer	0.000111	0.000785	CcSEcCtD
Carfilzomib—Musculoskeletal discomfort—Estradiol—prostate cancer	0.000111	0.000784	CcSEcCtD
Carfilzomib—Nausea—Ethinyl Estradiol—prostate cancer	0.000111	0.000784	CcSEcCtD
Carfilzomib—Hepatic failure—Doxorubicin—prostate cancer	0.000111	0.000783	CcSEcCtD
Carfilzomib—Asthenia—Goserelin—prostate cancer	0.00011	0.000779	CcSEcCtD
Carfilzomib—Insomnia—Estradiol—prostate cancer	0.00011	0.000778	CcSEcCtD
Carfilzomib—Hypoaesthesia—Docetaxel—prostate cancer	0.00011	0.000776	CcSEcCtD
Carfilzomib—Cardiac failure congestive—Doxorubicin—prostate cancer	0.00011	0.000776	CcSEcCtD
Carfilzomib—Asthenia—Conjugated Estrogens—prostate cancer	0.000109	0.000772	CcSEcCtD
Carfilzomib—Oedema peripheral—Docetaxel—prostate cancer	0.000109	0.000769	CcSEcCtD
Carfilzomib—Dyspnoea—Estradiol—prostate cancer	0.000109	0.000767	CcSEcCtD
Carfilzomib—Anorexia—Mitoxantrone—prostate cancer	0.000108	0.000764	CcSEcCtD
Carfilzomib—Hyponatraemia—Epirubicin—prostate cancer	0.000108	0.000764	CcSEcCtD
Carfilzomib—Renal failure acute—Doxorubicin—prostate cancer	0.000108	0.000763	CcSEcCtD
Carfilzomib—Pain in extremity—Epirubicin—prostate cancer	0.000108	0.000761	CcSEcCtD
Carfilzomib—Hyperglycaemia—Prednisone—prostate cancer	0.000107	0.000758	CcSEcCtD
Carfilzomib—Anaemia—Etoposide—prostate cancer	0.000107	0.000755	CcSEcCtD
Carfilzomib—Hypoaesthesia—Capecitabine—prostate cancer	0.000106	0.000752	CcSEcCtD
Carfilzomib—Decreased appetite—Estradiol—prostate cancer	0.000106	0.000748	CcSEcCtD
Carfilzomib—Oedema peripheral—Capecitabine—prostate cancer	0.000105	0.000744	CcSEcCtD
Carfilzomib—Diarrhoea—Goserelin—prostate cancer	0.000105	0.000743	CcSEcCtD
Carfilzomib—Fatigue—Estradiol—prostate cancer	0.000105	0.000742	CcSEcCtD
Carfilzomib—Acute coronary syndrome—Prednisone—prostate cancer	0.000105	0.000739	CcSEcCtD
Carfilzomib—Pain—Estradiol—prostate cancer	0.000104	0.000736	CcSEcCtD
Carfilzomib—Constipation—Estradiol—prostate cancer	0.000104	0.000736	CcSEcCtD
Carfilzomib—Diarrhoea—Conjugated Estrogens—prostate cancer	0.000104	0.000736	CcSEcCtD
Carfilzomib—Neuropathy peripheral—Prednisone—prostate cancer	0.000104	0.000735	CcSEcCtD
Carfilzomib—Leukopenia—Etoposide—prostate cancer	0.000104	0.000732	CcSEcCtD
Carfilzomib—Musculoskeletal discomfort—Mitoxantrone—prostate cancer	0.000103	0.000731	CcSEcCtD
Carfilzomib—Cardiac disorder—Docetaxel—prostate cancer	0.000102	0.000724	CcSEcCtD
Carfilzomib—Cardiac arrest—Epirubicin—prostate cancer	0.000102	0.000723	CcSEcCtD
Carfilzomib—Dizziness—Goserelin—prostate cancer	0.000102	0.000718	CcSEcCtD
Carfilzomib—Dyspnoea—Mitoxantrone—prostate cancer	0.000101	0.000715	CcSEcCtD
Carfilzomib—Cough—Etoposide—prostate cancer	0.000101	0.000713	CcSEcCtD
Carfilzomib—Blood creatinine increased—Epirubicin—prostate cancer	0.000101	0.000713	CcSEcCtD
Carfilzomib—Dizziness—Conjugated Estrogens—prostate cancer	0.000101	0.000711	CcSEcCtD
Carfilzomib—Hyponatraemia—Doxorubicin—prostate cancer	0.0001	0.000707	CcSEcCtD
Carfilzomib—Hypertension—Etoposide—prostate cancer	9.99e-05	0.000706	CcSEcCtD
Carfilzomib—Pain in extremity—Doxorubicin—prostate cancer	9.96e-05	0.000704	CcSEcCtD
Carfilzomib—Cardiac disorder—Capecitabine—prostate cancer	9.92e-05	0.000701	CcSEcCtD
Carfilzomib—Chills—Docetaxel—prostate cancer	9.91e-05	0.0007	CcSEcCtD
Carfilzomib—Decreased appetite—Mitoxantrone—prostate cancer	9.87e-05	0.000697	CcSEcCtD
Carfilzomib—Hypokalaemia—Epirubicin—prostate cancer	9.8e-05	0.000692	CcSEcCtD
Carfilzomib—Fatigue—Mitoxantrone—prostate cancer	9.79e-05	0.000691	CcSEcCtD
Carfilzomib—Vomiting—Goserelin—prostate cancer	9.77e-05	0.00069	CcSEcCtD
Carfilzomib—Pain—Mitoxantrone—prostate cancer	9.71e-05	0.000686	CcSEcCtD
Carfilzomib—Constipation—Mitoxantrone—prostate cancer	9.71e-05	0.000686	CcSEcCtD
Carfilzomib—Aspartate aminotransferase increased—Epirubicin—prostate cancer	9.7e-05	0.000685	CcSEcCtD
Carfilzomib—Vomiting—Conjugated Estrogens—prostate cancer	9.68e-05	0.000684	CcSEcCtD
Carfilzomib—Body temperature increased—Estradiol—prostate cancer	9.63e-05	0.00068	CcSEcCtD
Carfilzomib—Headache—Goserelin—prostate cancer	9.63e-05	0.00068	CcSEcCtD
Carfilzomib—Chills—Capecitabine—prostate cancer	9.59e-05	0.000678	CcSEcCtD
Carfilzomib—Headache—Conjugated Estrogens—prostate cancer	9.53e-05	0.000674	CcSEcCtD
Carfilzomib—Cardiac arrest—Doxorubicin—prostate cancer	9.47e-05	0.000669	CcSEcCtD
Carfilzomib—Infection—Etoposide—prostate cancer	9.38e-05	0.000663	CcSEcCtD
Carfilzomib—Blood creatinine increased—Doxorubicin—prostate cancer	9.33e-05	0.00066	CcSEcCtD
Carfilzomib—Back pain—Docetaxel—prostate cancer	9.3e-05	0.000657	CcSEcCtD
Carfilzomib—Thrombocytopenia—Etoposide—prostate cancer	9.24e-05	0.000653	CcSEcCtD
Carfilzomib—Muscle spasms—Docetaxel—prostate cancer	9.24e-05	0.000653	CcSEcCtD
Carfilzomib—Nausea—Goserelin—prostate cancer	9.13e-05	0.000645	CcSEcCtD
Carfilzomib—Hypokalaemia—Doxorubicin—prostate cancer	9.07e-05	0.000641	CcSEcCtD
Carfilzomib—Nausea—Conjugated Estrogens—prostate cancer	9.04e-05	0.000639	CcSEcCtD
Carfilzomib—Back pain—Capecitabine—prostate cancer	9e-05	0.000636	CcSEcCtD
Carfilzomib—Anorexia—Etoposide—prostate cancer	9e-05	0.000636	CcSEcCtD
Carfilzomib—Body temperature increased—Mitoxantrone—prostate cancer	8.97e-05	0.000634	CcSEcCtD
Carfilzomib—Aspartate aminotransferase increased—Doxorubicin—prostate cancer	8.97e-05	0.000634	CcSEcCtD
Carfilzomib—Muscle spasms—Capecitabine—prostate cancer	8.95e-05	0.000632	CcSEcCtD
Carfilzomib—Anaemia—Docetaxel—prostate cancer	8.89e-05	0.000628	CcSEcCtD
Carfilzomib—Asthenia—Estradiol—prostate cancer	8.74e-05	0.000618	CcSEcCtD
Carfilzomib—Neutropenia—Epirubicin—prostate cancer	8.7e-05	0.000615	CcSEcCtD
Carfilzomib—Upper respiratory tract infection—Epirubicin—prostate cancer	8.65e-05	0.000611	CcSEcCtD
Carfilzomib—PSMB8—Diflorasone—Prednisone—prostate cancer	8.64e-05	0.0254	CbGdCrCtD
Carfilzomib—Leukopenia—Docetaxel—prostate cancer	8.61e-05	0.000608	CcSEcCtD
Carfilzomib—Anaemia—Capecitabine—prostate cancer	8.6e-05	0.000608	CcSEcCtD
Carfilzomib—Dyspnoea—Etoposide—prostate cancer	8.42e-05	0.000595	CcSEcCtD
Carfilzomib—Hyperglycaemia—Epirubicin—prostate cancer	8.39e-05	0.000593	CcSEcCtD
Carfilzomib—Cough—Docetaxel—prostate cancer	8.39e-05	0.000593	CcSEcCtD
Carfilzomib—Pneumonia—Epirubicin—prostate cancer	8.35e-05	0.00059	CcSEcCtD
Carfilzomib—Diarrhoea—Estradiol—prostate cancer	8.33e-05	0.000589	CcSEcCtD
Carfilzomib—Leukopenia—Capecitabine—prostate cancer	8.33e-05	0.000589	CcSEcCtD
Carfilzomib—Hypertension—Docetaxel—prostate cancer	8.3e-05	0.000586	CcSEcCtD
Carfilzomib—Decreased appetite—Etoposide—prostate cancer	8.21e-05	0.00058	CcSEcCtD
Carfilzomib—Arthralgia—Docetaxel—prostate cancer	8.18e-05	0.000578	CcSEcCtD
Carfilzomib—Renal failure—Epirubicin—prostate cancer	8.16e-05	0.000576	CcSEcCtD
Carfilzomib—Asthenia—Mitoxantrone—prostate cancer	8.14e-05	0.000575	CcSEcCtD
Carfilzomib—Fatigue—Etoposide—prostate cancer	8.14e-05	0.000575	CcSEcCtD
Carfilzomib—Neuropathy peripheral—Epirubicin—prostate cancer	8.13e-05	0.000575	CcSEcCtD
Carfilzomib—Cough—Capecitabine—prostate cancer	8.12e-05	0.000574	CcSEcCtD
Carfilzomib—Constipation—Etoposide—prostate cancer	8.07e-05	0.00057	CcSEcCtD
Carfilzomib—Pain—Etoposide—prostate cancer	8.07e-05	0.00057	CcSEcCtD
Carfilzomib—Dizziness—Estradiol—prostate cancer	8.05e-05	0.000569	CcSEcCtD
Carfilzomib—Neutropenia—Doxorubicin—prostate cancer	8.05e-05	0.000569	CcSEcCtD
Carfilzomib—Hypertension—Capecitabine—prostate cancer	8.04e-05	0.000568	CcSEcCtD
Carfilzomib—Upper respiratory tract infection—Doxorubicin—prostate cancer	8e-05	0.000565	CcSEcCtD
Carfilzomib—Arthralgia—Capecitabine—prostate cancer	7.92e-05	0.00056	CcSEcCtD
Carfilzomib—Infection—Docetaxel—prostate cancer	7.79e-05	0.000551	CcSEcCtD
Carfilzomib—Hyperglycaemia—Doxorubicin—prostate cancer	7.77e-05	0.000549	CcSEcCtD
Carfilzomib—Diarrhoea—Mitoxantrone—prostate cancer	7.77e-05	0.000549	CcSEcCtD
Carfilzomib—Vomiting—Estradiol—prostate cancer	7.74e-05	0.000547	CcSEcCtD
Carfilzomib—Pneumonia—Doxorubicin—prostate cancer	7.72e-05	0.000546	CcSEcCtD
Carfilzomib—Thrombocytopenia—Docetaxel—prostate cancer	7.68e-05	0.000543	CcSEcCtD
Carfilzomib—Anaemia—Prednisone—prostate cancer	7.66e-05	0.000541	CcSEcCtD
Carfilzomib—Headache—Estradiol—prostate cancer	7.63e-05	0.000539	CcSEcCtD
Carfilzomib—Renal failure—Doxorubicin—prostate cancer	7.55e-05	0.000533	CcSEcCtD
Carfilzomib—Infection—Capecitabine—prostate cancer	7.55e-05	0.000533	CcSEcCtD
Carfilzomib—Neuropathy peripheral—Doxorubicin—prostate cancer	7.53e-05	0.000532	CcSEcCtD
Carfilzomib—Anorexia—Docetaxel—prostate cancer	7.48e-05	0.000528	CcSEcCtD
Carfilzomib—Body temperature increased—Etoposide—prostate cancer	7.46e-05	0.000527	CcSEcCtD
Carfilzomib—Thrombocytopenia—Capecitabine—prostate cancer	7.44e-05	0.000526	CcSEcCtD
Carfilzomib—Hypoaesthesia—Epirubicin—prostate cancer	7.41e-05	0.000524	CcSEcCtD
Carfilzomib—Oedema peripheral—Epirubicin—prostate cancer	7.34e-05	0.000519	CcSEcCtD
Carfilzomib—Anorexia—Capecitabine—prostate cancer	7.24e-05	0.000512	CcSEcCtD
Carfilzomib—Nausea—Estradiol—prostate cancer	7.24e-05	0.000511	CcSEcCtD
Carfilzomib—Vomiting—Mitoxantrone—prostate cancer	7.22e-05	0.00051	CcSEcCtD
Carfilzomib—Hypertension—Prednisone—prostate cancer	7.16e-05	0.000506	CcSEcCtD
Carfilzomib—Musculoskeletal discomfort—Docetaxel—prostate cancer	7.15e-05	0.000505	CcSEcCtD
Carfilzomib—Headache—Mitoxantrone—prostate cancer	7.11e-05	0.000502	CcSEcCtD
Carfilzomib—Insomnia—Docetaxel—prostate cancer	7.1e-05	0.000501	CcSEcCtD
Carfilzomib—Arthralgia—Prednisone—prostate cancer	7.06e-05	0.000499	CcSEcCtD
Carfilzomib—Dyspnoea—Docetaxel—prostate cancer	6.99e-05	0.000494	CcSEcCtD
Carfilzomib—Musculoskeletal discomfort—Capecitabine—prostate cancer	6.92e-05	0.000489	CcSEcCtD
Carfilzomib—Cardiac disorder—Epirubicin—prostate cancer	6.91e-05	0.000488	CcSEcCtD
Carfilzomib—Insomnia—Capecitabine—prostate cancer	6.87e-05	0.000485	CcSEcCtD
Carfilzomib—Hypoaesthesia—Doxorubicin—prostate cancer	6.86e-05	0.000485	CcSEcCtD
Carfilzomib—Decreased appetite—Docetaxel—prostate cancer	6.82e-05	0.000482	CcSEcCtD
Carfilzomib—Oedema peripheral—Doxorubicin—prostate cancer	6.79e-05	0.00048	CcSEcCtD
Carfilzomib—Asthenia—Etoposide—prostate cancer	6.77e-05	0.000479	CcSEcCtD
Carfilzomib—Dyspnoea—Capecitabine—prostate cancer	6.77e-05	0.000479	CcSEcCtD
Carfilzomib—Fatigue—Docetaxel—prostate cancer	6.76e-05	0.000478	CcSEcCtD
Carfilzomib—Nausea—Mitoxantrone—prostate cancer	6.74e-05	0.000476	CcSEcCtD
Carfilzomib—Infection—Prednisone—prostate cancer	6.72e-05	0.000475	CcSEcCtD
Carfilzomib—Constipation—Docetaxel—prostate cancer	6.71e-05	0.000474	CcSEcCtD
Carfilzomib—Pain—Docetaxel—prostate cancer	6.71e-05	0.000474	CcSEcCtD
Carfilzomib—Chills—Epirubicin—prostate cancer	6.68e-05	0.000472	CcSEcCtD
Carfilzomib—Decreased appetite—Capecitabine—prostate cancer	6.6e-05	0.000467	CcSEcCtD
Carfilzomib—Fatigue—Capecitabine—prostate cancer	6.55e-05	0.000463	CcSEcCtD
Carfilzomib—Pain—Capecitabine—prostate cancer	6.5e-05	0.000459	CcSEcCtD
Carfilzomib—Constipation—Capecitabine—prostate cancer	6.5e-05	0.000459	CcSEcCtD
Carfilzomib—Diarrhoea—Etoposide—prostate cancer	6.46e-05	0.000456	CcSEcCtD
Carfilzomib—Anorexia—Prednisone—prostate cancer	6.45e-05	0.000456	CcSEcCtD
Carfilzomib—Cardiac disorder—Doxorubicin—prostate cancer	6.4e-05	0.000452	CcSEcCtD
Carfilzomib—Back pain—Epirubicin—prostate cancer	6.27e-05	0.000443	CcSEcCtD
Carfilzomib—Dizziness—Etoposide—prostate cancer	6.24e-05	0.000441	CcSEcCtD
Carfilzomib—Muscle spasms—Epirubicin—prostate cancer	6.23e-05	0.000441	CcSEcCtD
Carfilzomib—Body temperature increased—Docetaxel—prostate cancer	6.2e-05	0.000438	CcSEcCtD
Carfilzomib—Chills—Doxorubicin—prostate cancer	6.18e-05	0.000437	CcSEcCtD
Carfilzomib—Musculoskeletal discomfort—Prednisone—prostate cancer	6.16e-05	0.000436	CcSEcCtD
Carfilzomib—Insomnia—Prednisone—prostate cancer	6.12e-05	0.000432	CcSEcCtD
Carfilzomib—Body temperature increased—Capecitabine—prostate cancer	6e-05	0.000424	CcSEcCtD
Carfilzomib—Vomiting—Etoposide—prostate cancer	6e-05	0.000424	CcSEcCtD
Carfilzomib—Anaemia—Epirubicin—prostate cancer	5.99e-05	0.000423	CcSEcCtD
Carfilzomib—Headache—Etoposide—prostate cancer	5.91e-05	0.000418	CcSEcCtD
Carfilzomib—Decreased appetite—Prednisone—prostate cancer	5.88e-05	0.000416	CcSEcCtD
Carfilzomib—Fatigue—Prednisone—prostate cancer	5.83e-05	0.000412	CcSEcCtD
Carfilzomib—Leukopenia—Epirubicin—prostate cancer	5.8e-05	0.00041	CcSEcCtD
Carfilzomib—Back pain—Doxorubicin—prostate cancer	5.8e-05	0.00041	CcSEcCtD
Carfilzomib—Constipation—Prednisone—prostate cancer	5.79e-05	0.000409	CcSEcCtD
Carfilzomib—Muscle spasms—Doxorubicin—prostate cancer	5.77e-05	0.000408	CcSEcCtD
Carfilzomib—Cough—Epirubicin—prostate cancer	5.66e-05	0.0004	CcSEcCtD
Carfilzomib—Asthenia—Docetaxel—prostate cancer	5.63e-05	0.000398	CcSEcCtD
Carfilzomib—Nausea—Etoposide—prostate cancer	5.61e-05	0.000396	CcSEcCtD
Carfilzomib—Hypertension—Epirubicin—prostate cancer	5.6e-05	0.000396	CcSEcCtD
Carfilzomib—Anaemia—Doxorubicin—prostate cancer	5.55e-05	0.000392	CcSEcCtD
Carfilzomib—Arthralgia—Epirubicin—prostate cancer	5.52e-05	0.00039	CcSEcCtD
Carfilzomib—Asthenia—Capecitabine—prostate cancer	5.45e-05	0.000385	CcSEcCtD
Carfilzomib—Leukopenia—Doxorubicin—prostate cancer	5.37e-05	0.000379	CcSEcCtD
Carfilzomib—Diarrhoea—Docetaxel—prostate cancer	5.37e-05	0.000379	CcSEcCtD
Carfilzomib—Body temperature increased—Prednisone—prostate cancer	5.35e-05	0.000378	CcSEcCtD
Carfilzomib—Infection—Epirubicin—prostate cancer	5.26e-05	0.000371	CcSEcCtD
Carfilzomib—Cough—Doxorubicin—prostate cancer	5.24e-05	0.00037	CcSEcCtD
Carfilzomib—Diarrhoea—Capecitabine—prostate cancer	5.2e-05	0.000367	CcSEcCtD
Carfilzomib—Dizziness—Docetaxel—prostate cancer	5.19e-05	0.000367	CcSEcCtD
Carfilzomib—Thrombocytopenia—Epirubicin—prostate cancer	5.18e-05	0.000366	CcSEcCtD
Carfilzomib—Hypertension—Doxorubicin—prostate cancer	5.18e-05	0.000366	CcSEcCtD
Carfilzomib—Arthralgia—Doxorubicin—prostate cancer	5.11e-05	0.000361	CcSEcCtD
Carfilzomib—Anorexia—Epirubicin—prostate cancer	5.04e-05	0.000356	CcSEcCtD
Carfilzomib—Dizziness—Capecitabine—prostate cancer	5.02e-05	0.000355	CcSEcCtD
Carfilzomib—Vomiting—Docetaxel—prostate cancer	4.99e-05	0.000352	CcSEcCtD
Carfilzomib—Headache—Docetaxel—prostate cancer	4.92e-05	0.000347	CcSEcCtD
Carfilzomib—Infection—Doxorubicin—prostate cancer	4.86e-05	0.000344	CcSEcCtD
Carfilzomib—Asthenia—Prednisone—prostate cancer	4.85e-05	0.000343	CcSEcCtD
Carfilzomib—Vomiting—Capecitabine—prostate cancer	4.83e-05	0.000341	CcSEcCtD
Carfilzomib—Musculoskeletal discomfort—Epirubicin—prostate cancer	4.82e-05	0.000341	CcSEcCtD
Carfilzomib—Thrombocytopenia—Doxorubicin—prostate cancer	4.79e-05	0.000339	CcSEcCtD
Carfilzomib—Insomnia—Epirubicin—prostate cancer	4.79e-05	0.000338	CcSEcCtD
Carfilzomib—Headache—Capecitabine—prostate cancer	4.76e-05	0.000336	CcSEcCtD
Carfilzomib—Dyspnoea—Epirubicin—prostate cancer	4.72e-05	0.000333	CcSEcCtD
Carfilzomib—Anorexia—Doxorubicin—prostate cancer	4.67e-05	0.00033	CcSEcCtD
Carfilzomib—Nausea—Docetaxel—prostate cancer	4.66e-05	0.000329	CcSEcCtD
Carfilzomib—PSMB8—Dexamethasone—Prednisone—prostate cancer	4.63e-05	0.0136	CbGdCrCtD
Carfilzomib—PSMB8—Betamethasone—Prednisone—prostate cancer	4.63e-05	0.0136	CbGdCrCtD
Carfilzomib—Diarrhoea—Prednisone—prostate cancer	4.63e-05	0.000327	CcSEcCtD
Carfilzomib—Decreased appetite—Epirubicin—prostate cancer	4.6e-05	0.000325	CcSEcCtD
Carfilzomib—Fatigue—Epirubicin—prostate cancer	4.56e-05	0.000322	CcSEcCtD
Carfilzomib—Constipation—Epirubicin—prostate cancer	4.53e-05	0.00032	CcSEcCtD
Carfilzomib—Pain—Epirubicin—prostate cancer	4.53e-05	0.00032	CcSEcCtD
Carfilzomib—Nausea—Capecitabine—prostate cancer	4.51e-05	0.000319	CcSEcCtD
Carfilzomib—Dizziness—Prednisone—prostate cancer	4.47e-05	0.000316	CcSEcCtD
Carfilzomib—Musculoskeletal discomfort—Doxorubicin—prostate cancer	4.46e-05	0.000315	CcSEcCtD
Carfilzomib—Insomnia—Doxorubicin—prostate cancer	4.43e-05	0.000313	CcSEcCtD
Carfilzomib—Dyspnoea—Doxorubicin—prostate cancer	4.37e-05	0.000308	CcSEcCtD
Carfilzomib—Vomiting—Prednisone—prostate cancer	4.3e-05	0.000304	CcSEcCtD
Carfilzomib—Decreased appetite—Doxorubicin—prostate cancer	4.26e-05	0.000301	CcSEcCtD
Carfilzomib—Headache—Prednisone—prostate cancer	4.24e-05	0.0003	CcSEcCtD
Carfilzomib—Fatigue—Doxorubicin—prostate cancer	4.22e-05	0.000298	CcSEcCtD
Carfilzomib—Constipation—Doxorubicin—prostate cancer	4.19e-05	0.000296	CcSEcCtD
Carfilzomib—Pain—Doxorubicin—prostate cancer	4.19e-05	0.000296	CcSEcCtD
Carfilzomib—Body temperature increased—Epirubicin—prostate cancer	4.18e-05	0.000296	CcSEcCtD
Carfilzomib—Nausea—Prednisone—prostate cancer	4.02e-05	0.000284	CcSEcCtD
Carfilzomib—Body temperature increased—Doxorubicin—prostate cancer	3.87e-05	0.000274	CcSEcCtD
Carfilzomib—Asthenia—Epirubicin—prostate cancer	3.8e-05	0.000268	CcSEcCtD
Carfilzomib—Diarrhoea—Epirubicin—prostate cancer	3.62e-05	0.000256	CcSEcCtD
Carfilzomib—Asthenia—Doxorubicin—prostate cancer	3.51e-05	0.000248	CcSEcCtD
Carfilzomib—Dizziness—Epirubicin—prostate cancer	3.5e-05	0.000247	CcSEcCtD
Carfilzomib—Vomiting—Epirubicin—prostate cancer	3.36e-05	0.000238	CcSEcCtD
Carfilzomib—Diarrhoea—Doxorubicin—prostate cancer	3.35e-05	0.000237	CcSEcCtD
Carfilzomib—Headache—Epirubicin—prostate cancer	3.32e-05	0.000234	CcSEcCtD
Carfilzomib—Dizziness—Doxorubicin—prostate cancer	3.24e-05	0.000229	CcSEcCtD
Carfilzomib—Nausea—Epirubicin—prostate cancer	3.14e-05	0.000222	CcSEcCtD
Carfilzomib—Vomiting—Doxorubicin—prostate cancer	3.11e-05	0.00022	CcSEcCtD
Carfilzomib—Headache—Doxorubicin—prostate cancer	3.07e-05	0.000217	CcSEcCtD
Carfilzomib—Nausea—Doxorubicin—prostate cancer	2.91e-05	0.000206	CcSEcCtD
Carfilzomib—PSMB1—Immune System—EGFR—prostate cancer	3.52e-06	2.42e-05	CbGpPWpGaD
Carfilzomib—PSMB1—Signaling Pathways—NOS3—prostate cancer	3.51e-06	2.42e-05	CbGpPWpGaD
Carfilzomib—PSMB2—Signaling Pathways—NOS3—prostate cancer	3.51e-06	2.42e-05	CbGpPWpGaD
Carfilzomib—PSMB5—Signaling Pathways—NOS3—prostate cancer	3.51e-06	2.42e-05	CbGpPWpGaD
Carfilzomib—PSMB8—Signaling Pathways—FGF2—prostate cancer	3.51e-06	2.41e-05	CbGpPWpGaD
Carfilzomib—PSMB9—Signaling Pathways—EP300—prostate cancer	3.51e-06	2.41e-05	CbGpPWpGaD
Carfilzomib—PSMB8—Immune System—EGFR—prostate cancer	3.47e-06	2.39e-05	CbGpPWpGaD
Carfilzomib—PSMB8—Signaling Pathways—NOS3—prostate cancer	3.46e-06	2.38e-05	CbGpPWpGaD
Carfilzomib—PSMB10—Signaling Pathways—SRC—prostate cancer	3.43e-06	2.36e-05	CbGpPWpGaD
Carfilzomib—PSMB2—Signaling Pathways—JAK2—prostate cancer	3.41e-06	2.35e-05	CbGpPWpGaD
Carfilzomib—PSMB5—Signaling Pathways—JAK2—prostate cancer	3.41e-06	2.35e-05	CbGpPWpGaD
Carfilzomib—PSMB1—Signaling Pathways—JAK2—prostate cancer	3.41e-06	2.35e-05	CbGpPWpGaD
Carfilzomib—PSMB9—Signaling Pathways—SRC—prostate cancer	3.41e-06	2.35e-05	CbGpPWpGaD
Carfilzomib—ABCB1—Metabolism—NCOA3—prostate cancer	3.4e-06	2.34e-05	CbGpPWpGaD
Carfilzomib—PSMB8—Signaling Pathways—JAK2—prostate cancer	3.37e-06	2.31e-05	CbGpPWpGaD
Carfilzomib—PSMB5—Metabolism—PTEN—prostate cancer	3.35e-06	2.3e-05	CbGpPWpGaD
Carfilzomib—PSMB2—Metabolism—PTEN—prostate cancer	3.35e-06	2.3e-05	CbGpPWpGaD
Carfilzomib—PSMB1—Metabolism—PTEN—prostate cancer	3.35e-06	2.3e-05	CbGpPWpGaD
Carfilzomib—PSMB10—Signaling Pathways—VEGFA—prostate cancer	3.34e-06	2.3e-05	CbGpPWpGaD
Carfilzomib—PSMB5—Signaling Pathways—MDM2—prostate cancer	3.33e-06	2.29e-05	CbGpPWpGaD
Carfilzomib—PSMB2—Signaling Pathways—MDM2—prostate cancer	3.33e-06	2.29e-05	CbGpPWpGaD
Carfilzomib—PSMB1—Signaling Pathways—MDM2—prostate cancer	3.33e-06	2.29e-05	CbGpPWpGaD
Carfilzomib—PSMB1—Immune System—KRAS—prostate cancer	3.33e-06	2.29e-05	CbGpPWpGaD
Carfilzomib—PSMB5—Immune System—KRAS—prostate cancer	3.33e-06	2.29e-05	CbGpPWpGaD
Carfilzomib—PSMB2—Immune System—KRAS—prostate cancer	3.33e-06	2.29e-05	CbGpPWpGaD
Carfilzomib—PSMB5—Disease—MYC—prostate cancer	3.32e-06	2.29e-05	CbGpPWpGaD
Carfilzomib—PSMB1—Disease—MYC—prostate cancer	3.32e-06	2.29e-05	CbGpPWpGaD
Carfilzomib—PSMB2—Disease—MYC—prostate cancer	3.32e-06	2.29e-05	CbGpPWpGaD
Carfilzomib—PSMB9—Signaling Pathways—VEGFA—prostate cancer	3.32e-06	2.28e-05	CbGpPWpGaD
Carfilzomib—PSMB5—Disease—TGFB1—prostate cancer	3.32e-06	2.28e-05	CbGpPWpGaD
Carfilzomib—PSMB2—Disease—TGFB1—prostate cancer	3.32e-06	2.28e-05	CbGpPWpGaD
Carfilzomib—PSMB1—Disease—TGFB1—prostate cancer	3.32e-06	2.28e-05	CbGpPWpGaD
Carfilzomib—PSMB10—Signaling Pathways—STAT3—prostate cancer	3.31e-06	2.27e-05	CbGpPWpGaD
Carfilzomib—PSMB8—Metabolism—PTEN—prostate cancer	3.3e-06	2.27e-05	CbGpPWpGaD
Carfilzomib—PSMB10—Disease—IL6—prostate cancer	3.3e-06	2.27e-05	CbGpPWpGaD
Carfilzomib—PSMB10—Immune System—AKT1—prostate cancer	3.3e-06	2.27e-05	CbGpPWpGaD
Carfilzomib—PSMB9—Signaling Pathways—STAT3—prostate cancer	3.29e-06	2.26e-05	CbGpPWpGaD
Carfilzomib—PSMB1—Signaling Pathways—ERBB2—prostate cancer	3.29e-06	2.26e-05	CbGpPWpGaD
Carfilzomib—PSMB2—Signaling Pathways—ERBB2—prostate cancer	3.29e-06	2.26e-05	CbGpPWpGaD
Carfilzomib—PSMB5—Signaling Pathways—ERBB2—prostate cancer	3.29e-06	2.26e-05	CbGpPWpGaD
Carfilzomib—PSMB8—Signaling Pathways—MDM2—prostate cancer	3.29e-06	2.26e-05	CbGpPWpGaD
Carfilzomib—PSMB9—Disease—IL6—prostate cancer	3.28e-06	2.26e-05	CbGpPWpGaD
Carfilzomib—PSMB8—Immune System—KRAS—prostate cancer	3.28e-06	2.26e-05	CbGpPWpGaD
Carfilzomib—PSMB9—Immune System—AKT1—prostate cancer	3.28e-06	2.25e-05	CbGpPWpGaD
Carfilzomib—PSMB8—Disease—MYC—prostate cancer	3.28e-06	2.25e-05	CbGpPWpGaD
Carfilzomib—PSMB10—Gene Expression—AKT1—prostate cancer	3.28e-06	2.25e-05	CbGpPWpGaD
Carfilzomib—PSMB8—Disease—TGFB1—prostate cancer	3.27e-06	2.25e-05	CbGpPWpGaD
Carfilzomib—PSMB9—Gene Expression—AKT1—prostate cancer	3.26e-06	2.24e-05	CbGpPWpGaD
Carfilzomib—PSMB2—Disease—EGFR—prostate cancer	3.25e-06	2.24e-05	CbGpPWpGaD
Carfilzomib—PSMB5—Disease—EGFR—prostate cancer	3.25e-06	2.24e-05	CbGpPWpGaD
Carfilzomib—PSMB1—Disease—EGFR—prostate cancer	3.25e-06	2.24e-05	CbGpPWpGaD
Carfilzomib—ABCB1—Metabolism—HPGDS—prostate cancer	3.25e-06	2.23e-05	CbGpPWpGaD
Carfilzomib—PSMB5—Signaling Pathways—PIK3CB—prostate cancer	3.24e-06	2.23e-05	CbGpPWpGaD
Carfilzomib—PSMB1—Signaling Pathways—PIK3CB—prostate cancer	3.24e-06	2.23e-05	CbGpPWpGaD
Carfilzomib—PSMB2—Signaling Pathways—PIK3CB—prostate cancer	3.24e-06	2.23e-05	CbGpPWpGaD
Carfilzomib—PSMB8—Signaling Pathways—ERBB2—prostate cancer	3.24e-06	2.23e-05	CbGpPWpGaD
Carfilzomib—ABCB1—Metabolism—CYP2C19—prostate cancer	3.22e-06	2.22e-05	CbGpPWpGaD
Carfilzomib—PSMB8—Disease—EGFR—prostate cancer	3.21e-06	2.2e-05	CbGpPWpGaD
Carfilzomib—PSMB8—Signaling Pathways—PIK3CB—prostate cancer	3.2e-06	2.2e-05	CbGpPWpGaD
Carfilzomib—PSMB5—Metabolism—EP300—prostate cancer	3.2e-06	2.2e-05	CbGpPWpGaD
Carfilzomib—PSMB2—Metabolism—EP300—prostate cancer	3.2e-06	2.2e-05	CbGpPWpGaD
Carfilzomib—PSMB1—Metabolism—EP300—prostate cancer	3.2e-06	2.2e-05	CbGpPWpGaD
Carfilzomib—PSMB8—Metabolism—EP300—prostate cancer	3.15e-06	2.17e-05	CbGpPWpGaD
Carfilzomib—ABCB1—Metabolism—GSTT1—prostate cancer	3.15e-06	2.16e-05	CbGpPWpGaD
Carfilzomib—ABCB1—Metabolism—ACHE—prostate cancer	3.15e-06	2.16e-05	CbGpPWpGaD
Carfilzomib—PSMB10—Metabolism—PIK3CA—prostate cancer	3.12e-06	2.14e-05	CbGpPWpGaD
Carfilzomib—PSMB1—Signaling Pathways—CXCL8—prostate cancer	3.12e-06	2.14e-05	CbGpPWpGaD
Carfilzomib—PSMB2—Signaling Pathways—CXCL8—prostate cancer	3.12e-06	2.14e-05	CbGpPWpGaD
Carfilzomib—PSMB5—Signaling Pathways—CXCL8—prostate cancer	3.12e-06	2.14e-05	CbGpPWpGaD
Carfilzomib—ABCB1—Metabolism—CYP2A6—prostate cancer	3.11e-06	2.14e-05	CbGpPWpGaD
Carfilzomib—PSMB9—Metabolism—PIK3CA—prostate cancer	3.1e-06	2.13e-05	CbGpPWpGaD
Carfilzomib—PSMB10—Signaling Pathways—MYC—prostate cancer	3.07e-06	2.11e-05	CbGpPWpGaD
Carfilzomib—PSMB5—Disease—KRAS—prostate cancer	3.07e-06	2.11e-05	CbGpPWpGaD
Carfilzomib—PSMB2—Disease—KRAS—prostate cancer	3.07e-06	2.11e-05	CbGpPWpGaD
Carfilzomib—PSMB1—Disease—KRAS—prostate cancer	3.07e-06	2.11e-05	CbGpPWpGaD
Carfilzomib—PSMB8—Signaling Pathways—CXCL8—prostate cancer	3.07e-06	2.11e-05	CbGpPWpGaD
Carfilzomib—PSMB10—Signaling Pathways—TGFB1—prostate cancer	3.06e-06	2.11e-05	CbGpPWpGaD
Carfilzomib—PSMB9—Signaling Pathways—MYC—prostate cancer	3.06e-06	2.1e-05	CbGpPWpGaD
Carfilzomib—PSMB2—Immune System—PIK3CA—prostate cancer	3.06e-06	2.1e-05	CbGpPWpGaD
Carfilzomib—PSMB1—Immune System—PIK3CA—prostate cancer	3.06e-06	2.1e-05	CbGpPWpGaD
Carfilzomib—PSMB5—Immune System—PIK3CA—prostate cancer	3.06e-06	2.1e-05	CbGpPWpGaD
Carfilzomib—ABCB1—Integrated Pancreatic Cancer Pathway—AKT1—prostate cancer	3.05e-06	2.1e-05	CbGpPWpGaD
Carfilzomib—PSMB9—Signaling Pathways—TGFB1—prostate cancer	3.05e-06	2.1e-05	CbGpPWpGaD
Carfilzomib—PSMB2—Signaling Pathways—CDKN1B—prostate cancer	3.04e-06	2.09e-05	CbGpPWpGaD
Carfilzomib—PSMB5—Signaling Pathways—CDKN1B—prostate cancer	3.04e-06	2.09e-05	CbGpPWpGaD
Carfilzomib—PSMB1—Signaling Pathways—CDKN1B—prostate cancer	3.04e-06	2.09e-05	CbGpPWpGaD
Carfilzomib—PSMB10—Disease—AKT1—prostate cancer	3.04e-06	2.09e-05	CbGpPWpGaD
Carfilzomib—PSMB8—Disease—KRAS—prostate cancer	3.03e-06	2.08e-05	CbGpPWpGaD
Carfilzomib—PSMB9—Disease—AKT1—prostate cancer	3.03e-06	2.08e-05	CbGpPWpGaD
Carfilzomib—ABCB1—Metabolism—AKR1C3—prostate cancer	3.03e-06	2.08e-05	CbGpPWpGaD
Carfilzomib—PSMB8—Immune System—PIK3CA—prostate cancer	3.01e-06	2.07e-05	CbGpPWpGaD
Carfilzomib—ABCB1—Metabolism—PRKACB—prostate cancer	3.01e-06	2.07e-05	CbGpPWpGaD
Carfilzomib—PSMB10—Signaling Pathways—EGFR—prostate cancer	3e-06	2.07e-05	CbGpPWpGaD
Carfilzomib—PSMB8—Signaling Pathways—CDKN1B—prostate cancer	3e-06	2.06e-05	CbGpPWpGaD
Carfilzomib—PSMB9—Signaling Pathways—EGFR—prostate cancer	2.99e-06	2.06e-05	CbGpPWpGaD
Carfilzomib—PSMB2—Signaling Pathways—CASP3—prostate cancer	2.98e-06	2.05e-05	CbGpPWpGaD
Carfilzomib—PSMB5—Signaling Pathways—CASP3—prostate cancer	2.98e-06	2.05e-05	CbGpPWpGaD
Carfilzomib—PSMB1—Signaling Pathways—CASP3—prostate cancer	2.98e-06	2.05e-05	CbGpPWpGaD
Carfilzomib—ABCB1—Metabolism—CYP17A1—prostate cancer	2.98e-06	2.05e-05	CbGpPWpGaD
Carfilzomib—PSMB5—Signaling Pathways—IL2—prostate cancer	2.98e-06	2.05e-05	CbGpPWpGaD
Carfilzomib—PSMB2—Signaling Pathways—IL2—prostate cancer	2.98e-06	2.05e-05	CbGpPWpGaD
Carfilzomib—PSMB1—Signaling Pathways—IL2—prostate cancer	2.98e-06	2.05e-05	CbGpPWpGaD
Carfilzomib—ABCB1—Transmembrane transport of small molecules—CREBBP—prostate cancer	2.95e-06	2.03e-05	CbGpPWpGaD
Carfilzomib—PSMB8—Signaling Pathways—CASP3—prostate cancer	2.94e-06	2.02e-05	CbGpPWpGaD
Carfilzomib—PSMB8—Signaling Pathways—IL2—prostate cancer	2.94e-06	2.02e-05	CbGpPWpGaD
Carfilzomib—PSMB1—Signaling Pathways—CCND1—prostate cancer	2.9e-06	2e-05	CbGpPWpGaD
Carfilzomib—PSMB2—Signaling Pathways—CCND1—prostate cancer	2.9e-06	2e-05	CbGpPWpGaD
Carfilzomib—PSMB5—Signaling Pathways—CCND1—prostate cancer	2.9e-06	2e-05	CbGpPWpGaD
Carfilzomib—PSMB2—Signaling Pathways—CTNNB1—prostate cancer	2.87e-06	1.98e-05	CbGpPWpGaD
Carfilzomib—PSMB5—Signaling Pathways—CTNNB1—prostate cancer	2.87e-06	1.98e-05	CbGpPWpGaD
Carfilzomib—PSMB1—Signaling Pathways—CTNNB1—prostate cancer	2.87e-06	1.98e-05	CbGpPWpGaD
Carfilzomib—PSMB8—Signaling Pathways—CCND1—prostate cancer	2.86e-06	1.97e-05	CbGpPWpGaD
Carfilzomib—ABCB1—Metabolism—NCOA2—prostate cancer	2.84e-06	1.95e-05	CbGpPWpGaD
Carfilzomib—PSMB10—Signaling Pathways—KRAS—prostate cancer	2.84e-06	1.95e-05	CbGpPWpGaD
Carfilzomib—PSMB8—Signaling Pathways—CTNNB1—prostate cancer	2.83e-06	1.95e-05	CbGpPWpGaD
Carfilzomib—PSMB9—Signaling Pathways—KRAS—prostate cancer	2.83e-06	1.94e-05	CbGpPWpGaD
Carfilzomib—PSMB5—Disease—PIK3CA—prostate cancer	2.82e-06	1.94e-05	CbGpPWpGaD
Carfilzomib—PSMB1—Disease—PIK3CA—prostate cancer	2.82e-06	1.94e-05	CbGpPWpGaD
Carfilzomib—PSMB2—Disease—PIK3CA—prostate cancer	2.82e-06	1.94e-05	CbGpPWpGaD
Carfilzomib—PSMB2—Signaling Pathways—MMP9—prostate cancer	2.82e-06	1.94e-05	CbGpPWpGaD
Carfilzomib—PSMB1—Signaling Pathways—MMP9—prostate cancer	2.82e-06	1.94e-05	CbGpPWpGaD
Carfilzomib—PSMB5—Signaling Pathways—MMP9—prostate cancer	2.82e-06	1.94e-05	CbGpPWpGaD
Carfilzomib—PSMB2—Signaling Pathways—CDKN1A—prostate cancer	2.81e-06	1.93e-05	CbGpPWpGaD
Carfilzomib—PSMB5—Signaling Pathways—CDKN1A—prostate cancer	2.81e-06	1.93e-05	CbGpPWpGaD
Carfilzomib—PSMB1—Signaling Pathways—CDKN1A—prostate cancer	2.81e-06	1.93e-05	CbGpPWpGaD
Carfilzomib—PSMB2—Signaling Pathways—PTEN—prostate cancer	2.8e-06	1.93e-05	CbGpPWpGaD
Carfilzomib—PSMB1—Signaling Pathways—PTEN—prostate cancer	2.8e-06	1.93e-05	CbGpPWpGaD
Carfilzomib—PSMB5—Signaling Pathways—PTEN—prostate cancer	2.8e-06	1.93e-05	CbGpPWpGaD
Carfilzomib—PSMB8—Disease—PIK3CA—prostate cancer	2.78e-06	1.91e-05	CbGpPWpGaD
Carfilzomib—PSMB8—Signaling Pathways—MMP9—prostate cancer	2.78e-06	1.91e-05	CbGpPWpGaD
Carfilzomib—PSMB8—Signaling Pathways—CDKN1A—prostate cancer	2.77e-06	1.9e-05	CbGpPWpGaD
Carfilzomib—PSMB8—Signaling Pathways—PTEN—prostate cancer	2.76e-06	1.9e-05	CbGpPWpGaD
Carfilzomib—ABCB1—Metabolism—SLC5A5—prostate cancer	2.71e-06	1.86e-05	CbGpPWpGaD
Carfilzomib—PSMB1—Immune System—IL6—prostate cancer	2.71e-06	1.86e-05	CbGpPWpGaD
Carfilzomib—PSMB5—Immune System—IL6—prostate cancer	2.71e-06	1.86e-05	CbGpPWpGaD
Carfilzomib—PSMB2—Immune System—IL6—prostate cancer	2.71e-06	1.86e-05	CbGpPWpGaD
Carfilzomib—PSMB2—Signaling Pathways—EP300—prostate cancer	2.67e-06	1.84e-05	CbGpPWpGaD
Carfilzomib—PSMB1—Signaling Pathways—EP300—prostate cancer	2.67e-06	1.84e-05	CbGpPWpGaD
Carfilzomib—PSMB5—Signaling Pathways—EP300—prostate cancer	2.67e-06	1.84e-05	CbGpPWpGaD
Carfilzomib—PSMB8—Immune System—IL6—prostate cancer	2.67e-06	1.84e-05	CbGpPWpGaD
Carfilzomib—ABCB1—Metabolism—CYP2E1—prostate cancer	2.65e-06	1.82e-05	CbGpPWpGaD
Carfilzomib—PSMB8—Signaling Pathways—EP300—prostate cancer	2.63e-06	1.81e-05	CbGpPWpGaD
Carfilzomib—ABCB1—Metabolism—NQO1—prostate cancer	2.62e-06	1.8e-05	CbGpPWpGaD
Carfilzomib—PSMB10—Signaling Pathways—PIK3CA—prostate cancer	2.61e-06	1.79e-05	CbGpPWpGaD
Carfilzomib—PSMB5—Signaling Pathways—SRC—prostate cancer	2.6e-06	1.79e-05	CbGpPWpGaD
Carfilzomib—PSMB2—Signaling Pathways—SRC—prostate cancer	2.6e-06	1.79e-05	CbGpPWpGaD
Carfilzomib—PSMB1—Signaling Pathways—SRC—prostate cancer	2.6e-06	1.79e-05	CbGpPWpGaD
Carfilzomib—PSMB9—Signaling Pathways—PIK3CA—prostate cancer	2.6e-06	1.78e-05	CbGpPWpGaD
Carfilzomib—ABCB1—Metabolism—TH—prostate cancer	2.58e-06	1.77e-05	CbGpPWpGaD
Carfilzomib—PSMB8—Signaling Pathways—SRC—prostate cancer	2.56e-06	1.76e-05	CbGpPWpGaD
Carfilzomib—ABCB1—Metabolism—CYP3A4—prostate cancer	2.55e-06	1.75e-05	CbGpPWpGaD
Carfilzomib—PSMB10—Metabolism—AKT1—prostate cancer	2.55e-06	1.75e-05	CbGpPWpGaD
Carfilzomib—PSMB9—Metabolism—AKT1—prostate cancer	2.54e-06	1.74e-05	CbGpPWpGaD
Carfilzomib—PSMB5—Signaling Pathways—VEGFA—prostate cancer	2.53e-06	1.74e-05	CbGpPWpGaD
Carfilzomib—PSMB1—Signaling Pathways—VEGFA—prostate cancer	2.53e-06	1.74e-05	CbGpPWpGaD
Carfilzomib—PSMB2—Signaling Pathways—VEGFA—prostate cancer	2.53e-06	1.74e-05	CbGpPWpGaD
Carfilzomib—PSMB10—Signaling Pathways—TP53—prostate cancer	2.52e-06	1.73e-05	CbGpPWpGaD
Carfilzomib—PSMB9—Signaling Pathways—TP53—prostate cancer	2.51e-06	1.73e-05	CbGpPWpGaD
Carfilzomib—ABCB1—Metabolism—CYP1B1—prostate cancer	2.51e-06	1.72e-05	CbGpPWpGaD
Carfilzomib—PSMB1—Signaling Pathways—STAT3—prostate cancer	2.51e-06	1.72e-05	CbGpPWpGaD
Carfilzomib—PSMB5—Signaling Pathways—STAT3—prostate cancer	2.51e-06	1.72e-05	CbGpPWpGaD
Carfilzomib—PSMB2—Signaling Pathways—STAT3—prostate cancer	2.51e-06	1.72e-05	CbGpPWpGaD
Carfilzomib—PSMB1—Disease—IL6—prostate cancer	2.5e-06	1.72e-05	CbGpPWpGaD
Carfilzomib—PSMB5—Disease—IL6—prostate cancer	2.5e-06	1.72e-05	CbGpPWpGaD
Carfilzomib—PSMB2—Disease—IL6—prostate cancer	2.5e-06	1.72e-05	CbGpPWpGaD
Carfilzomib—PSMB1—Immune System—AKT1—prostate cancer	2.5e-06	1.72e-05	CbGpPWpGaD
Carfilzomib—PSMB5—Immune System—AKT1—prostate cancer	2.5e-06	1.72e-05	CbGpPWpGaD
Carfilzomib—PSMB2—Immune System—AKT1—prostate cancer	2.5e-06	1.72e-05	CbGpPWpGaD
Carfilzomib—PSMB8—Signaling Pathways—VEGFA—prostate cancer	2.49e-06	1.72e-05	CbGpPWpGaD
Carfilzomib—PSMB2—Gene Expression—AKT1—prostate cancer	2.48e-06	1.71e-05	CbGpPWpGaD
Carfilzomib—PSMB1—Gene Expression—AKT1—prostate cancer	2.48e-06	1.71e-05	CbGpPWpGaD
Carfilzomib—PSMB5—Gene Expression—AKT1—prostate cancer	2.48e-06	1.71e-05	CbGpPWpGaD
Carfilzomib—PSMB8—Signaling Pathways—STAT3—prostate cancer	2.47e-06	1.7e-05	CbGpPWpGaD
Carfilzomib—PSMB8—Disease—IL6—prostate cancer	2.46e-06	1.69e-05	CbGpPWpGaD
Carfilzomib—PSMB8—Immune System—AKT1—prostate cancer	2.46e-06	1.69e-05	CbGpPWpGaD
Carfilzomib—PSMB8—Gene Expression—AKT1—prostate cancer	2.45e-06	1.68e-05	CbGpPWpGaD
Carfilzomib—ABCB1—Metabolism—GGT1—prostate cancer	2.43e-06	1.67e-05	CbGpPWpGaD
Carfilzomib—ABCB1—Metabolism—NCOA1—prostate cancer	2.39e-06	1.65e-05	CbGpPWpGaD
Carfilzomib—PSMB2—Metabolism—PIK3CA—prostate cancer	2.36e-06	1.63e-05	CbGpPWpGaD
Carfilzomib—PSMB5—Metabolism—PIK3CA—prostate cancer	2.36e-06	1.63e-05	CbGpPWpGaD
Carfilzomib—PSMB1—Metabolism—PIK3CA—prostate cancer	2.36e-06	1.63e-05	CbGpPWpGaD
Carfilzomib—ABCB1—Metabolism—CYP19A1—prostate cancer	2.36e-06	1.62e-05	CbGpPWpGaD
Carfilzomib—PSMB8—Metabolism—PIK3CA—prostate cancer	2.33e-06	1.6e-05	CbGpPWpGaD
Carfilzomib—PSMB1—Signaling Pathways—MYC—prostate cancer	2.33e-06	1.6e-05	CbGpPWpGaD
Carfilzomib—PSMB5—Signaling Pathways—MYC—prostate cancer	2.33e-06	1.6e-05	CbGpPWpGaD
Carfilzomib—PSMB2—Signaling Pathways—MYC—prostate cancer	2.33e-06	1.6e-05	CbGpPWpGaD
Carfilzomib—PSMB5—Signaling Pathways—TGFB1—prostate cancer	2.32e-06	1.6e-05	CbGpPWpGaD
Carfilzomib—PSMB2—Signaling Pathways—TGFB1—prostate cancer	2.32e-06	1.6e-05	CbGpPWpGaD
Carfilzomib—PSMB1—Signaling Pathways—TGFB1—prostate cancer	2.32e-06	1.6e-05	CbGpPWpGaD
Carfilzomib—PSMB10—Signaling Pathways—IL6—prostate cancer	2.31e-06	1.59e-05	CbGpPWpGaD
Carfilzomib—PSMB5—Disease—AKT1—prostate cancer	2.31e-06	1.59e-05	CbGpPWpGaD
Carfilzomib—PSMB2—Disease—AKT1—prostate cancer	2.31e-06	1.59e-05	CbGpPWpGaD
Carfilzomib—PSMB1—Disease—AKT1—prostate cancer	2.31e-06	1.59e-05	CbGpPWpGaD
Carfilzomib—PSMB9—Signaling Pathways—IL6—prostate cancer	2.3e-06	1.58e-05	CbGpPWpGaD
Carfilzomib—PSMB8—Signaling Pathways—MYC—prostate cancer	2.3e-06	1.58e-05	CbGpPWpGaD
Carfilzomib—PSMB8—Signaling Pathways—TGFB1—prostate cancer	2.29e-06	1.57e-05	CbGpPWpGaD
Carfilzomib—PSMB5—Signaling Pathways—EGFR—prostate cancer	2.28e-06	1.57e-05	CbGpPWpGaD
Carfilzomib—PSMB1—Signaling Pathways—EGFR—prostate cancer	2.28e-06	1.57e-05	CbGpPWpGaD
Carfilzomib—PSMB2—Signaling Pathways—EGFR—prostate cancer	2.28e-06	1.57e-05	CbGpPWpGaD
Carfilzomib—ABCB1—Metabolism—RXRA—prostate cancer	2.28e-06	1.56e-05	CbGpPWpGaD
Carfilzomib—PSMB8—Disease—AKT1—prostate cancer	2.27e-06	1.56e-05	CbGpPWpGaD
Carfilzomib—PSMB8—Signaling Pathways—EGFR—prostate cancer	2.25e-06	1.54e-05	CbGpPWpGaD
Carfilzomib—ABCB1—Metabolism—COMT—prostate cancer	2.19e-06	1.51e-05	CbGpPWpGaD
Carfilzomib—ABCB1—Metabolism—GSTP1—prostate cancer	2.18e-06	1.5e-05	CbGpPWpGaD
Carfilzomib—PSMB1—Signaling Pathways—KRAS—prostate cancer	2.15e-06	1.48e-05	CbGpPWpGaD
Carfilzomib—PSMB2—Signaling Pathways—KRAS—prostate cancer	2.15e-06	1.48e-05	CbGpPWpGaD
Carfilzomib—PSMB5—Signaling Pathways—KRAS—prostate cancer	2.15e-06	1.48e-05	CbGpPWpGaD
Carfilzomib—ABCB1—Metabolism—ITPR1—prostate cancer	2.15e-06	1.48e-05	CbGpPWpGaD
Carfilzomib—PSMB10—Signaling Pathways—AKT1—prostate cancer	2.13e-06	1.46e-05	CbGpPWpGaD
Carfilzomib—PSMB8—Signaling Pathways—KRAS—prostate cancer	2.12e-06	1.46e-05	CbGpPWpGaD
Carfilzomib—PSMB9—Signaling Pathways—AKT1—prostate cancer	2.12e-06	1.46e-05	CbGpPWpGaD
Carfilzomib—ABCB1—Metabolism—TYMS—prostate cancer	2.03e-06	1.39e-05	CbGpPWpGaD
Carfilzomib—ABCB1—Metabolism—GSTM1—prostate cancer	2e-06	1.38e-05	CbGpPWpGaD
Carfilzomib—PSMB2—Signaling Pathways—PIK3CA—prostate cancer	1.98e-06	1.36e-05	CbGpPWpGaD
Carfilzomib—PSMB1—Signaling Pathways—PIK3CA—prostate cancer	1.98e-06	1.36e-05	CbGpPWpGaD
Carfilzomib—PSMB5—Signaling Pathways—PIK3CA—prostate cancer	1.98e-06	1.36e-05	CbGpPWpGaD
Carfilzomib—ABCB1—Metabolism—LPL—prostate cancer	1.97e-06	1.35e-05	CbGpPWpGaD
Carfilzomib—PSMB8—Signaling Pathways—PIK3CA—prostate cancer	1.95e-06	1.34e-05	CbGpPWpGaD
Carfilzomib—PSMB1—Metabolism—AKT1—prostate cancer	1.93e-06	1.33e-05	CbGpPWpGaD
Carfilzomib—PSMB5—Metabolism—AKT1—prostate cancer	1.93e-06	1.33e-05	CbGpPWpGaD
Carfilzomib—PSMB2—Metabolism—AKT1—prostate cancer	1.93e-06	1.33e-05	CbGpPWpGaD
Carfilzomib—PSMB1—Signaling Pathways—TP53—prostate cancer	1.91e-06	1.31e-05	CbGpPWpGaD
Carfilzomib—PSMB5—Signaling Pathways—TP53—prostate cancer	1.91e-06	1.31e-05	CbGpPWpGaD
Carfilzomib—PSMB2—Signaling Pathways—TP53—prostate cancer	1.91e-06	1.31e-05	CbGpPWpGaD
Carfilzomib—PSMB8—Metabolism—AKT1—prostate cancer	1.9e-06	1.31e-05	CbGpPWpGaD
Carfilzomib—ABCB1—Metabolism—CYP1A1—prostate cancer	1.9e-06	1.31e-05	CbGpPWpGaD
Carfilzomib—PSMB8—Signaling Pathways—TP53—prostate cancer	1.89e-06	1.3e-05	CbGpPWpGaD
Carfilzomib—ABCB1—Metabolism—ERCC2—prostate cancer	1.89e-06	1.3e-05	CbGpPWpGaD
Carfilzomib—ABCB1—Metabolism—MTHFR—prostate cancer	1.77e-06	1.22e-05	CbGpPWpGaD
Carfilzomib—PSMB5—Signaling Pathways—IL6—prostate cancer	1.75e-06	1.2e-05	CbGpPWpGaD
Carfilzomib—PSMB1—Signaling Pathways—IL6—prostate cancer	1.75e-06	1.2e-05	CbGpPWpGaD
Carfilzomib—PSMB2—Signaling Pathways—IL6—prostate cancer	1.75e-06	1.2e-05	CbGpPWpGaD
Carfilzomib—ABCB1—Metabolism—PPARA—prostate cancer	1.74e-06	1.2e-05	CbGpPWpGaD
Carfilzomib—PSMB8—Signaling Pathways—IL6—prostate cancer	1.73e-06	1.19e-05	CbGpPWpGaD
Carfilzomib—ABCB1—Metabolism—CAV1—prostate cancer	1.63e-06	1.12e-05	CbGpPWpGaD
Carfilzomib—PSMB5—Signaling Pathways—AKT1—prostate cancer	1.61e-06	1.11e-05	CbGpPWpGaD
Carfilzomib—PSMB1—Signaling Pathways—AKT1—prostate cancer	1.61e-06	1.11e-05	CbGpPWpGaD
Carfilzomib—PSMB2—Signaling Pathways—AKT1—prostate cancer	1.61e-06	1.11e-05	CbGpPWpGaD
Carfilzomib—PSMB8—Signaling Pathways—AKT1—prostate cancer	1.59e-06	1.09e-05	CbGpPWpGaD
Carfilzomib—ABCB1—Metabolism—PIK3CG—prostate cancer	1.49e-06	1.02e-05	CbGpPWpGaD
Carfilzomib—ABCB1—Metabolism—INS—prostate cancer	1.41e-06	9.69e-06	CbGpPWpGaD
Carfilzomib—ABCB1—Metabolism—CREBBP—prostate cancer	1.38e-06	9.49e-06	CbGpPWpGaD
Carfilzomib—ABCB1—Metabolism—PIK3CD—prostate cancer	1.31e-06	9e-06	CbGpPWpGaD
Carfilzomib—ABCB1—Metabolism—NOS3—prostate cancer	1.24e-06	8.5e-06	CbGpPWpGaD
Carfilzomib—ABCB1—Metabolism—PIK3CB—prostate cancer	1.14e-06	7.84e-06	CbGpPWpGaD
Carfilzomib—ABCB1—Metabolism—PTGS2—prostate cancer	1.13e-06	7.77e-06	CbGpPWpGaD
Carfilzomib—ABCB1—Metabolism—PTEN—prostate cancer	9.86e-07	6.78e-06	CbGpPWpGaD
Carfilzomib—ABCB1—Metabolism—EP300—prostate cancer	9.4e-07	6.46e-06	CbGpPWpGaD
Carfilzomib—ABCB1—Metabolism—PIK3CA—prostate cancer	6.95e-07	4.78e-06	CbGpPWpGaD
Carfilzomib—ABCB1—Metabolism—AKT1—prostate cancer	5.68e-07	3.91e-06	CbGpPWpGaD
